华安证券给予泽璟制药买入评级：吉卡昔替尼将参与医保谈判，多抗组合覆盖优势领域

Group 1 - The core viewpoint of the article is that Huazhong Securities has given a "buy" rating to Zai Lab (688266.SH) based on its improving financial condition and ongoing commercialization efforts [1] - The financial status of Zai Lab is reported to be continuously improving, with balanced and stable expenditures [1] - Zai Lab is making steady progress in its commercialization process, particularly with the drug Gika Xiqi (吉卡昔替尼片) preparing for medical insurance negotiations [1] - The company is advancing multiple specific antibodies into clinical trials, focusing on combination therapies targeting various pathways [1]